In light of the recent PGT-A class action lawsuit filings in a court in Florida, Vitrolife Group issues the following statement

Vitrolife Group is aware that a PGT-A class action lawsuit has been filed against Vitrolife AB (publ), Vitrolife Inc and Igenomix USA, Inc in the court of the Southern District of Florida, although no formal complaint has been served yet. During the fourth quarter of 2024, similar class actions were initiated in the US against other peer companies providing PGT-A testing services. Vitrolife Group will, together with our legal counsel in the US, evaluate the class action and its potential scope and update the market in due course when further information is available.

Gothenburg, 5 March 2025
VITROLIFE AB (publ)
Bronwyn Brophy O’Connor, CEO

Contact:
Amelie Wilson, Investor Relations, awilson@vitrolife.com

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

Vitrolife Group is a global provider of medical devices and genetic testing solutions. Our vision is to enable people to fulfil the dream of having a healthy baby. Our mission is to be the leading global partner in reproductive health, striving for better treatment outcomes for patients. With 1,100 employees worldwide and headquarters in Gothenburg, Sweden, our products and services are available in over 125 countries through our direct presence and a network of distributors. Vitrolife AB (publ) is listed on Nasdaq Stockholm.